52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager

Autor: Basnet, S., Santos, J.M., Quixabeira, D.C.A., Clubb, J., Grönberg-Vähä-Koskela, S., Pakola, S., Kudling, T., Heiniö, C., Havunen, R., Cervera-Carrascon, V., Sorsa, S., Anttila, M., Kanerva, A., Hemminki, A.

Publikováno v: In Immuno-Oncology and Technology December 2022 16 Supplement 1

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.

Autor: Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Lähdeniemi IAK; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Sutinen E; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland., Räsänen J; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Borenius K; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mäyränpää MI; Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland., Aaltonen E; Faculty of Medicine, Medicum, University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Verschuren EW; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Ilonen I; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Aug 02; Vol. 12 (1), pp. 2241710. Date of Electronic Publication: 2023 Aug 02 (Print Publication: 2023).

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.

Autor: Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland., Grönberg-Vähä-Koskela SAM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; Helsinki University Hospital (HUS), 00029, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; Helsinki University Hospital (HUS), 00029, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland., Anttila M; Department of Pathology, Finnish Food Authority, 00790, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, 00290, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland.; TILT Biotherapeutics Ltd, 00290, Helsinki, Finland.; Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, and University of Helsinki, 00029, Helsinki, Finland.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2022 Dec 28; Vol. 28, pp. 59-73. Date of Electronic Publication: 2022 Dec 28 (Print Publication: 2023).

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.

Autor: Heiniö C; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland., Clubb J; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; TILT Biotherapeutics Ltd., 00270 Helsinki, Finland., Kudling T; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland., Quixabeira D; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; TILT Biotherapeutics Ltd., 00270 Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; TILT Biotherapeutics Ltd., 00270 Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital, 00270 Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; TILT Biotherapeutics Ltd., 00270 Helsinki, Finland., Tapper J; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00270 Helsinki, Finland., Kanerva A; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00270 Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Faculty of Medicine, TRIMM, RPU, University of Helsinki, 00270 Helsinki, Finland.; TILT Biotherapeutics Ltd., 00270 Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital, 00270 Helsinki, Finland.

Publikováno v: Diseases (Basel, Switzerland) [Diseases] 2022 Aug 08; Vol. 10 (3). Date of Electronic Publication: 2022 Aug 08.

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.

Autor: Clubb JHA; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Cervera Carrascón V; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Zheng V; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Salo T; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.; Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.; Oulu University Central Hospital, Oulu, Finland.; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Bäck L; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Aro K; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Tulokas S; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Loimu V; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Mar 07; Vol. 13, pp. 794251. Date of Electronic Publication: 2022 Mar 07 (Print Publication: 2022).